 "Sun Pharma")
The approval to Teva Pharmaceuticals (Teva) by the US Food and Drug Administration (USFDA) for the launch of the generic version of Absorica in the US market is a negative for Sun Pharmaceutical Industries (Sun Pharma). At annual revenues in the $100-120 million range, the drug — used in treating severe acne and certain types of skin cancers — is the largest specialty product in Sun Pharma’s US portfolio.
The launch of the product and the market share that Teva could take in the coming weeks could weigh on the stock, say analysts. The patent of the product is slated to
